ResMed
A global leader in digital health and connected medical devices, plus software solutions that support out-of-hospital care providers.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 8 % | 12 % | 18 % | 11 % | 9 % | 8 % | 7 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 35 % | 33 % | 32 % | 34 % | 36 % | 37 % | 37 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 15 % | 22 % | 21 % | 22 % | 27 % | 27 % | 28 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 7 % | 7 % | 7 % | 7 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
ResMed (NYSE: RMD, ASX: RMD) develops cloud-connected medical devices and software platforms aimed at treating and managing sleep apnea, COPD, and other chronic diseases. The company serves patients, healthcare professionals, and caregivers, providing solutions that enable better care and improve quality of life. Operating in over 120 countries, ResMed's business model focuses on selling medical devices and software subscriptions, generating revenue through product sales and recurring service fees. By reducing hospital visits and lowering healthcare costs, ResMed addresses the needs of both consumers and healthcare systems.
Keywords: medical devices, sleep apnea, COPD, chronic diseases, cloud-connected, healthcare, software platforms, patient care, caregivers, global.
Tech stack
Investments by ResMed
Edit
